Loading organizations...
§ Private Profile · Glasgow, Glasgow City, United Kingdom
Provides hiPS cardiomyocyte assay services for pharmaceutical and biotech clients, focused on preclinical cardiac safety.
Clyde Biosciences is a Glasgow, Scotland-based biotechnology company that develops advanced assays using human induced pluripotent stem cell cardiomyocytes and optical imaging technology to test preclinical drug toxicity. The organization operates on a service-based model providing cardiac electrophysiology data to major global pharmaceutical clients, generating an annual turnover of approximately £1 million. Operating with a team of seven employees and two consultants, the firm utilizes its proprietary CellOPTIQ platform to improve safety and arrhythmia detection in the broader drug discovery process. The enterprise originally spun out of the University of Glasgow and subsequently secured a £2 million Series A investment round led by venture firm Epidarex Capital to scale its commercial operations. Clyde Biosciences was founded in 2012 by Dr. Margaret Anne Craig, Professor Godfrey Smith, Dr. Francis Burton, and Professor Jon Cooper.
Clyde Biosciences has raised $2.9M across 1 funding round.
Clyde Biosciences has raised $2.9M in total across 1 funding round.
Clyde Biosciences has raised $2.9M across 1 funding round. Most recently, it raised $2.9M Series A in April 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 13, 2015 | $2.9M Series A | Epidarex Capital | Glasgow University Holdings, Scottish Enterprise | Announced |
Clyde Biosciences has raised $2.9M in total across 1 funding round.
Clyde Biosciences's investors include Epidarex Capital, Glasgow University Holdings, Scottish Enterprise.